FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2066009006> ?p ?o ?g. }

• W2066009006 endingPage "1467" @default.
• W2066009006 startingPage "1451" @default.
• W2066009006 abstract "Purpose. The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects of ximelagatran are reviewed. Summary. Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phase III clinical trials. After oral administration, ximelagatran is rapidly converted to its active metabolite, melagatran. Melagatran (after oral ximelagatran administration) predictably inhibits thrombin function without need for routine anticoagulation monitoring. Melagatran effectively inhibits both free and clot-bound thrombin—a potential pharmacodynamic advantage over heparin products. Melagatran has a half-life of 2.4–4.6 hours, necessitating twice-daily administration. Melagatran is primarily eliminated by the kidneys and has not been studied clinically in patients with severe renal failure. Ximelagatran has undergone 10 Phase III trials (6 for prophylaxis of venous thromboembolism [VTE] due to orthopedic surgery, 1 for initial treatment of VTE, 1 for long-term prevention of VTE recurrence, and 2 for stroke prophylaxis due to atrial fibrillation). Results were generally positive. AstraZeneca applied in December 2003 for marketing approval of ximelagatran for prevention of VTE after total knee replacement surgery, long-term prevention of VTE recurrence after standard therapy, and stroke prevention due to atrial fibrillation. FDA denied approval of ximelagatran for all indications, mainly because of increased rates of coronary artery disease events in ximelagatran recipients in some studies and the possibility of hepatic failure when the medication is used for long-term therapy. Conclusion. Ximelagatran has shown promise as a possible alternative to warfarin and other anticoagulants but will require further study to ensure its safety." @default.
• W2066009006 created "2016-06-24" @default.
• W2066009006 creator A5072273559 @default.
• W2066009006 date "2005-07-15" @default.
• W2066009006 modified "2023-10-03" @default.
• W2066009006 title "Ximelagatran: An orally active direct thrombin inhibitor" @default.
• W2066009006 cites W1489188437 @default.
• W2066009006 cites W1738640266 @default.
• W2066009006 cites W1804375307 @default.
• W2066009006 cites W1860102466 @default.
• W2066009006 cites W1966393469 @default.
• W2066009006 cites W1969343008 @default.
• W2066009006 cites W1977434798 @default.
• W2066009006 cites W1978506115 @default.
• W2066009006 cites W1980536507 @default.
• W2066009006 cites W1994783449 @default.
• W2066009006 cites W1995036763 @default.
• W2066009006 cites W1996063108 @default.
• W2066009006 cites W2009013630 @default.
• W2066009006 cites W2014736504 @default.
• W2066009006 cites W2016234199 @default.
• W2066009006 cites W2016810881 @default.
• W2066009006 cites W2019391438 @default.
• W2066009006 cites W2036872916 @default.
• W2066009006 cites W2038537842 @default.
• W2066009006 cites W2048313858 @default.
• W2066009006 cites W2054740753 @default.
• W2066009006 cites W2056443751 @default.
• W2066009006 cites W2057806510 @default.
• W2066009006 cites W2063916070 @default.
• W2066009006 cites W2067272751 @default.
• W2066009006 cites W2067559489 @default.
• W2066009006 cites W2078275792 @default.
• W2066009006 cites W2094796479 @default.
• W2066009006 cites W2096698984 @default.
• W2066009006 cites W2104486401 @default.
• W2066009006 cites W2107825824 @default.
• W2066009006 cites W2111979976 @default.
• W2066009006 cites W2112757583 @default.
• W2066009006 cites W2115841978 @default.
• W2066009006 cites W2119813866 @default.
• W2066009006 cites W2120439011 @default.
• W2066009006 cites W2121366426 @default.
• W2066009006 cites W2129804106 @default.
• W2066009006 cites W2135918458 @default.
• W2066009006 cites W2139511461 @default.
• W2066009006 cites W2152754892 @default.
• W2066009006 cites W2153196285 @default.
• W2066009006 cites W2157350867 @default.
• W2066009006 cites W2162955405 @default.
• W2066009006 cites W2167816835 @default.
• W2066009006 cites W2252603912 @default.
• W2066009006 cites W2327974959 @default.
• W2066009006 cites W2331935930 @default.
• W2066009006 cites W2617484322 @default.
• W2066009006 doi "https://doi.org/10.2146/ajhp040534" @default.
• W2066009006 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15998925" @default.
• W2066009006 hasPublicationYear "2005" @default.
• W2066009006 type Work @default.
• W2066009006 sameAs 2066009006 @default.
• W2066009006 citedByCount "22" @default.
• W2066009006 countsByYear W20660090062012 @default.
• W2066009006 countsByYear W20660090062013 @default.
• W2066009006 countsByYear W20660090062019 @default.
• W2066009006 countsByYear W20660090062020 @default.
• W2066009006 crossrefType "journal-article" @default.
• W2066009006 hasAuthorship W2066009006A5072273559 @default.
• W2066009006 hasConcept C126322002 @default.
• W2066009006 hasConcept C127413603 @default.
• W2066009006 hasConcept C141071460 @default.
• W2066009006 hasConcept C197934379 @default.
• W2066009006 hasConcept C2776301958 @default.
• W2066009006 hasConcept C2776710957 @default.
• W2066009006 hasConcept C2777292125 @default.
• W2066009006 hasConcept C2778205648 @default.
• W2066009006 hasConcept C2778810321 @default.
• W2066009006 hasConcept C2779161974 @default.
• W2066009006 hasConcept C2779630707 @default.
• W2066009006 hasConcept C2780645631 @default.
• W2066009006 hasConcept C42219234 @default.
• W2066009006 hasConcept C57002609 @default.
• W2066009006 hasConcept C71924100 @default.
• W2066009006 hasConcept C78519656 @default.
• W2066009006 hasConcept C89560881 @default.
• W2066009006 hasConcept C98274493 @default.
• W2066009006 hasConceptScore W2066009006C126322002 @default.
• W2066009006 hasConceptScore W2066009006C127413603 @default.
• W2066009006 hasConceptScore W2066009006C141071460 @default.
• W2066009006 hasConceptScore W2066009006C197934379 @default.
• W2066009006 hasConceptScore W2066009006C2776301958 @default.
• W2066009006 hasConceptScore W2066009006C2776710957 @default.
• W2066009006 hasConceptScore W2066009006C2777292125 @default.
• W2066009006 hasConceptScore W2066009006C2778205648 @default.
• W2066009006 hasConceptScore W2066009006C2778810321 @default.
• W2066009006 hasConceptScore W2066009006C2779161974 @default.
• W2066009006 hasConceptScore W2066009006C2779630707 @default.
• W2066009006 hasConceptScore W2066009006C2780645631 @default.
• W2066009006 hasConceptScore W2066009006C42219234 @default.

• next